



News Release

September 24, 2019

Unichem Pharmaceuticals Launches Generic Maxalt® – Rizatriptan ODT

Unichem Pharmaceuticals (USA), Inc. is pleased to announce the launch of Rizatriptan ODT Tablets, the latest addition to our growing portfolio.

Rizatriptan ODT is the generic version of Maxalt® ODT from Merck Sharp & Dohme Corp. Rizatriptan ODT is used to treat migraines. It helps to relieve headache, pain, and other migraine symptoms including nausea, vomiting, and sensitivity to light/sound. IQVIA recorded sales of \$22.7M and 15.2M tablets of Rizatriptan ODT during the last 12 months ending July 2019. Rizatriptan ODT is available in 5mg & 10mg – 9ct & 18ct bottles.

Unichem’s Senior Director of Marketing, Samuel Goodman, said the following regarding the launch: “Unichem is happy to add this new product to our portfolio of anti-inflammatory drugs, bringing healing and comfort to a growing number of patients.”

About Unichem Pharmaceuticals (USA), Inc:

Unichem Pharmaceuticals (USA), Inc. is a wholly owned subsidiary of Unichem Laboratories Limited (NSE: UNICHEMLAB). Unichem Pharmaceuticals has a growing list of US FDA approved products and a strong product pipeline to support our growth plans. Unichem Pharmaceutical’s focus is on providing quality and cost-effective products with reliable and efficient customer service.

Any interest in buying products please contact the below National Accounts Representatives.

Contact: Mary Rotunno

Contact: Neal Miller

Contact: Kaitlin Alexander

Phone: (201) 621-3710

Phone: (303) 886-1260

Phone: (201) 519-0802

Email: mrotunno@unichemusa.com

Email: nmiller@unichemusa.com

Email: kalexander@unichemusa.com

Disclaimer:

Estimates, expectations, and business plans in this release are forward-looking statements. Actual future results, including and without limitation, target dates, project plans, capacity costs, and other statements relating to any future business plans, may differ from our expectations. The information contained in this press release is accurate only as of the date each press release was originally issued. The matters discussed herein may also be affected by risks and uncertainties described from time to time within the Pharmaceutical industry. The company assumes no obligation to update any future occurrence and will not be held accountable for any use of this information.